Test Price
2,800 AEDโ Home Collection Available
DNM1 Gene Early Infantile Epileptic Encephalopathy Type 31 NGS Test in UAE | DNA Labs UAE
Executive Summary & Core Metrics
๐ฌ Diagnostic Sensitivity
99.9% analytical sensitivity for SNVs and indels in DNM1 via ISO 17025 and ISO 9001:2015 accredited NGS workflow. Orthogonal confirmation applied for all reportable variants.
๐ Home Collection Logistics
VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM across all UAE emirates. Hospital-grade specimen integrity from draw to lab.
๐งฌ Post-Test Genetic Counseling
Complimentary telephonic session with a DHA-licensed genetic counselor to interpret results, discuss inheritance patterns, and guide next steps for patient management.
๐ Insurance Verification
Direct billing confirmation via WhatsApp. Forward your insurance card to +971 54 548 8731 for real-time eligibility assessment.
Test Overview & Methodology
The DNM1 gene encodes dynamin-1, a protein essential for synaptic vesicle recycling at nerve terminals. Pathogenic variants in DNM1 cause Early Infantile Epileptic Encephalopathy Type 31, a severe neurological disorder characterised by drug-resistant seizures beginning in the first months of life, profound developmental delay, hypotonia, and often movement abnormalities. This targeted NGS test interrogates all coding exons and flanking splice regions of DNM1 at an average depth of 200X, enabling definitive molecular confirmation and prompt differentiation from other genetic epileptic encephalopathies. Accurate genetic diagnosis allows tailored antiepileptic drug selection and avoids unnecessary immunosuppressive or metabolic therapies.
Comparative Analytical Performance
| Feature | DNM1 Targeted NGS Test | Whole Exome Sequencing (WES) |
|---|---|---|
| Target Coverage | Single-gene DNM1 at 200X average depth | All ~20,000 genes at ~80X average depth |
| Analytical Sensitivity | >99.9% for SNVs and indels within DNM1 | ~98% genome-wide; variable per gene |
| Turnaround Time | 3โ4 weeks | 6โ8 weeks |
| Price (AED) | 2,800 | 4,500โ5,500 |
| Clinical Indication | High pre-test suspicion of EIEE31 guides rapid confirmation | Broad screening when phenotype is unresolved |
Physician Insight & Safety Protocols
โManaging a child with suspected early infantile epileptic encephalopathy demands both urgency and precision. This targeted DNM1 NGS test provides a definitive genetic answer within weeks, allowing clinicians to choose the most appropriate antiseizure regimen and avoid unnecessary trials of immunotherapy or metabolic therapies. I always emphasise that genotype-negative results do not exclude other monogenic epilepsies; comprehensive re-evaluation including EEG and MRI correlation remains essential. My commitment is to support each family with clarity, empathy, and evidence-based guidance throughout the diagnostic process.โ
โ Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory โ Medication Continuity
Critical Medication Warning
Never discontinue or adjust prescribed antiepileptic medications without direct instruction from your treating neurologist. Abrupt cessation may precipitate status epilepticus, which is a medical emergency requiring immediate hospital intervention.
Emergency Indicators โ Seek Emergency Care Immediately:
- Seizure activity lasting longer than 5 minutes or serial seizures without full recovery.
- Respiratory difficulty, cyanosis, or loss of consciousness.
- Sudden severe headache, vomiting, or altered mental status following a seizure.
Exclusion Criteria for Testing
Conditions That May Compromise Results
- History of allogeneic bone marrow or stem cell transplant โ donor-derived DNA may confound variant detection in blood.
- Inability to obtain informed consent from the legal guardian as required by UAE Federal Law No. 2 of 2019 concerning the Use of Information and Communication Technology in Health Fields and Federal Decree-Law No. 4 of 2016 on Medical Liability.
Patient FAQ & Clinical Guidance
1. What is the purpose of the DNM1 genetic test?
This test detects pathogenic variants in the DNM1 gene that cause early infantile epileptic encephalopathy type 31, enabling targeted treatment decisions. By sequencing all coding exons and splice junctions, the analysis identifies disease-causing mutations with high sensitivity. A positive result can end the diagnostic odyssey, guide antiepileptic therapy selection, and inform family planning through genetic counselling.
2. How is the sample collected and can a phlebotomist visit my home?
A small peripheral blood sample or a dried blood spot on FTA card is sufficient; we provide VIP mobile phlebotomy across all UAE emirates. Our trained phlebotomy team arrives with temperature-controlled transport containers compliant with ISO cold-chain standards. Service is available daily from 8 AM to 11 PM, and specimens are tracked continuously from collection to laboratory receipt.
3. What is the turnaround time and what support is provided after results are issued?
Results are delivered within 3โ4 weeks; a DHA-licensed genetic counsellor contacts you to explain the findings and their implications. You receive a comprehensive PDF report detailing variant classification, inheritance pattern, and clinical recommendations. The complimentary post-test counselling session ensures you understand the significance for the patient's management and any familial risks, fully aligned with UAE genetic counselling regulations.
UAE Regulatory & Data Privacy Adherence
Compliance & Data Protection Framework
All diagnostic testing and data handling at DNA Labs UAE fully comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Sample anonymity and secure data processing are enforced throughout the testing lifecycle. Clinical safety and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | DNM1 Gene Sequencing โ Early Infantile Epileptic Encephalopathy Type 31 NGS Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3โ4 weeks |
| Sample Type / Matrix | Peripheral whole blood (EDTA) or dried blood spot on FTA card |
| Methodology Used | Targeted Next-Generation Sequencing (NGS) at 200X average depth with orthogonal Sanger confirmation |
| ICD-10-CM Code | G40.4 |
| LOINC Code | 21636-6 |
| DHA Facility License & Address | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE โ DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians